LOXITANE IM Drug Patent Profile
✉ Email this page to a colleague
When do Loxitane Im patents expire, and when can generic versions of Loxitane Im launch?
Loxitane Im is a drug marketed by Actavis Labs Ut Inc and is included in one NDA.
The generic ingredient in LOXITANE IM is loxapine hydrochloride. There are eight drug master file entries for this compound. Additional details are available on the loxapine hydrochloride profile page.
Summary for LOXITANE IM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 13 |
| Clinical Trials: | 1 |
| Patent Applications: | 382 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | LOXITANE IM at DailyMed |
Recent Clinical Trials for LOXITANE IM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mylan Pharmaceuticals | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for LOXITANE IM
US Patents and Regulatory Information for LOXITANE IM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Labs Ut Inc | LOXITANE IM | loxapine hydrochloride | INJECTABLE;INJECTION | 018039-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LOXITANE IM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Actavis Labs Ut Inc | LOXITANE IM | loxapine hydrochloride | INJECTABLE;INJECTION | 018039-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LOXITANE IM
See the table below for patents covering LOXITANE IM around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Denmark | 118463 | ⤷ Try a Trial | |
| Switzerland | 481941 | Verfahren zur Herstellung basisch substituierter Heterocyclen | ⤷ Try a Trial |
| Switzerland | 450425 | Verfahren zur Herstellung 11-basisch substituierter Dibenz(b,f)(1,4)oxazepine | ⤷ Try a Trial |
| Belgium | 712114 | ⤷ Try a Trial | |
| Israel | 29571 | 11-SUBSTITUTED DIBENZO(B,F)-1,4-OXAZEPINES,DIBENZO(B,F)-1,4-THIAZEPINES AND DIBENZO(B,E)-1,4-DIAZEPINES AND THEIR PREPARATION | ⤷ Try a Trial |
| Germany | 1470426 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LOXITANE IM
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1389098 | SPC/GB13/055 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: LOXAPINE; REGISTERED: UK EU/1/13/823/001 20130220; UK EU/1/13/823/002 20130220 |
| 1389098 | 300609 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220 |
| 1389098 | 2013C/054 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LOXAPINE; AUTHORISATION NUMBER AND DATE: EU/1/13/823/001 20130225 |
| 1389098 | C300609 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
